scholarly journals Fabrication of a paper-based colorimetric molecular test for SARS-CoV-2

MethodsX ◽  
2021 ◽  
pp. 101586
Author(s):  
Jiangshan Wang ◽  
Andres Dextre ◽  
Ana Pascual-Garrigos ◽  
Josiah Levi Davidson ◽  
Darby McChesney ◽  
...  
Keyword(s):  
Molecular Test

What Every Neuropathologist Needs to Know: Practical Aspects and Pitfalls in Molecular Diagnosis of Brain Tumors

2021 ◽  
Author(s):  
J Stephen Nix ◽  
Cristiane M Ida
Keyword(s):  
Brain Tumors ◽  
Molecular Diagnosis ◽  
Genetic Alterations ◽  
Genetic Alteration ◽  
Molecular Testing ◽  
Test Results ◽  
Molecular Test ◽  
Molecular Tests ◽  
Clinically Significant ◽  
Selection Of

Abstract Molecular testing has become part of the routine diagnostic workup of brain tumors after the implementation of integrated histomolecular diagnoses in the 2016 WHO classification update. It is important for every neuropathologist to be aware of practical preanalytical, analytical, and postanalytical factors that impact the performance and interpretation of molecular tests. Prior to testing, optimizing tumor purity and tumor amount increases the ability of the molecular test to detect the genetic alteration of interest. Recognizing basic molecular testing platform analytical characteristics allows selection of the optimal platform for each clinicopathological scenario. Finally, postanalytical considerations to properly interpret molecular test results include understanding the clinical significance of the detected genetic alteration, recognizing that detected clinically significant genetic alterations are occasionally germline constitutional rather than somatic tumor-specific, and being cognizant that recommended and commonly used genetic nomenclature may differ. Potential pitfalls in brain tumor molecular diagnosis are also discussed.

scholarly journals Diagnosis of infection by SARS-COV-2: Is one molecular test enough?

2021 ◽  
Author(s):  
Antonella Mencacci ◽  
Maria Cristina Vedovati ◽  
Barbara Camilloni ◽  
Elio Cenci ◽  
Cecilia Becattini
Keyword(s):  
Molecular Test ◽  
Diagnosis Of Infection

scholarly journals Use of a rapid point‐of‐care molecular test in the triage of suspected COVID‐19 cases

2021 ◽  
Author(s):  
Marco Ciotti ◽  
Eleonora Nicolai ◽  
Fabbio Marcuccilli ◽  
Sergio Bernardini
Keyword(s):  
Point Of Care ◽  
Molecular Test

scholarly journals A paper-based colorimetric molecular test for SARS-CoV-2 in saliva

2021 ◽  
pp. 100076
Author(s):  
Josiah Levi Davidson ◽  
Jiangshan Wang ◽  
Murali Kannan Maruthamuthu ◽  
Andres Dextre ◽  
Ana Pascual-Garrigos ◽  
...  
Keyword(s):  
Molecular Test

The utility of rapid Group A streptococcus molecular testing compared with throat culture for the diagnosis of Group A streptococcal pharyngitis in a high-incidence rheumatic fever population.

2021 ◽  
Author(s):  
Amanda Taylor ◽  
Susan Morpeth ◽  
Rachel Webb ◽  
Susan Taylor
Keyword(s):  
New Zealand ◽  
Rheumatic Fever ◽  
Predictive Value ◽  
Gold Standard ◽  
Molecular Test ◽  
Throat Culture ◽  
High Incidence ◽  
Group A ◽  
Sensitivity Specificity ◽  
Culture Negative

Background: Group A Streptococcus (GAS) causes significant morbidity and mortality in New Zealand and is responsible for invasive disease and immune sequelae including acute Rheumatic Fever (ARF). Early treatment of GAS pharyngitis reduces the risk of ARF. In settings with a high-burden of GAS disease, a rapid GAS pharyngitis diagnostic test with a strong negative predictive value is needed to enable prompt and accurate treatment. Methods: This prospective study compares the Xpert® Xpress Strep A molecular test (Cepheid) to throat culture and a second molecular method, the BioGX Group A Streptococcus -OSR for BD MAX TM for the diagnosis of GAS pharyngitis. Throat swabs were collected from the emergency department and wards of Middlemore Hospital, New Zealand. The BioGX Group A Streptococcus - OSR for BD MAX TM , contributes to the composite gold-standard: throat culture or both molecular methods positive. Basic demographic, clinical and laboratory data was collected. Results: 205/214 swabs were suitable for analysis. 28/205 (13.7%) were GAS culture positive, 45/205 (22%) Xpert® Xpress Strep A positive and 38/205 (18.5%) BioGX positive. Compared to culture, the sensitivity, specificity, positive and negative predictive values of the Xpert® Xpress Strep A molecular test were 100%, 90.4%, 62.2% and 100%, respectively. Compared to the composite gold-standard, the sensitivity, specificity, PPV and NPV and were 100%, 95.8%, 84.4% and 100% respectively. 17 samples were Xpert® Xpress positive but culture-negative; 6 of these 17 swabs represent true positives with evidence of recent GAS infection. Ten samples were culture negative but both Xpert® Xpress and BioGX positive. Conclusion: The Xpert® Xpress Strep A molecular test is highly sensitive with a strong negative predictive value and rapid turnaround time. It can be safely introduced as a first line test for throat swabs in a high-incidence ARF population.

scholarly journals Is primary meningococcal arthritis in children more frequent than we expect? Two pediatric case reports revealed by molecular test

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
S. Ricci ◽  
A. Montemaggi ◽  
F. Nieddu ◽  
D. Serranti ◽  
G. Indolfi ◽  
...  
Keyword(s):  
Case Reports ◽  
Molecular Test ◽  
Pediatric Case

scholarly journals Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases

2021 ◽  
Author(s):  
Claire Cook ◽  
Naomi Patel ◽  
Kristin D'Silva ◽  
Tiffany T-Y Hsu ◽  
Michael DiIorio ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Inflammatory Myopathy ◽  
Vaccination Status ◽  
Antibody Responses ◽  
Molecular Test ◽  
Breakthrough Infection ◽  
Autoimmune Rheumatic Diseases ◽  
Autoimmune Rheumatic Disease ◽  
Systemic Autoimmune Rheumatic Disease ◽  
The Us

Objective To describe the characteristics of COVID-19 vaccine breakthrough infections among systemic autoimmune rheumatic disease (SARD) patients. Methods We identified SARDs patients in a large healthcare system with COVID-19 vaccination at least 14 days prior to a positive SARS-CoV-2 molecular test. Details of the SARD diagnosis, vaccination status, and COVID-19 infection were extracted. Results Of 340 confirmed COVID-19 infections among SARDs patients between December 11th, 2020 (date of first COVID-19 vaccine approval in the US) and July 30th, 2021, we identified 16 breakthrough infections. Seven (44%) received the Pfizer-BioNtech vaccine, five (31%) received the Moderna vaccine, and four (25%) received the Janssen/Johnson & Johnson vaccine. The most common SARDs included rheumatoid arthritis (6, 38%), inflammatory myopathy (3, 19%), and systemic lupus erythematosus (3, 19%). Rituximab (5, 31%), glucocorticoids (4, 25%), and mycophenolate mofetil (4, 25%) were the most frequent treatments. Among the breakthrough infections, 15 (93%) were symptomatic, six (38%) were hospitalized, one (6%) required mechanical ventilation, and two (13%) died. Conclusions Symptomatic, including severe, breakthrough infections were observed in SARDs patients; many were on treatments associated with attenuated antibody responses to vaccination. Further studies are needed to determine the rate of breakthrough infection associated with SARD treatments and other features.

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?

2016 ◽  
Vol 140 (4) ◽  
pp. 351-354 ◽  
Author(s):  
Alain C. Borczuk ◽  
Timothy Craig Allen
Keyword(s):  
Lung Cancer ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Moving Target ◽  
Molecular Test ◽  
Oncogenic Mutation ◽  
Programmed Death ◽  
Checkpoint Inhibitor Therapy ◽  
Prescribing Information

The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non–small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand-1 (PD-L1). The intense interest in drug development in this area has resulted in additional agents with associated diagnostics looming on the horizon in 2016. In the era of precision medicine, the paradigm of paired molecular target and molecular test, which serves as a model of oncogenic mutation-driven cancer therapy, is challenged by the proliferation of immunohistochemistry-based tests with different antibodies, instruments, and scoring. The difficulty inherent to targeted therapy aimed at a moving target is discussed, as well as the emerging challenges to pathologists and oncologists who seek to optimize care in this complex therapeutic arena.

Sign in / Sign up

Export Citation Format

Share Document